Psoriasis
Original Research
Eating Disorder Risk Factors and the Impact of Obesity in Patients With Psoriasis
Current evidence indicates that obesity may initiate psoriasis or worsen existing disease. Various factors contribute to the development of...
Original Research
Projected 2023 Cost Reduction From Tumor Necrosis Factor α Inhibitor Biosimilars in Dermatology: A National Medicare Analysis
To the Editor:
Although biologics provide major therapeutic benefits for dermatologic conditions, they also come with a substantial cost,...
Commentary
Considerations for the Use of Biologics in Pregnancy
Biologics have revolutionized dermatologic treatment, offering substantial relief from chronic and debilitating skin conditions such as psoriasis...
Original Research
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis
The National Psoriasis Foundation (NPF) treatment targets aim to achieve 1% or lower body surface area (BSA) affected after 3...
Latest News
Study Supports Efficacy of Home-Based Phototherapy for Psoriasis
"Efforts are needed to make home and office phototherapy more available to patients," the lead author said.
News from the FDA/CDC
Bimekizumab Gains FDA Approval for Psoriatic Arthritis, Axial Spondyloarthritis
The drug is the first and only dual IL-17A and IL-17F inhibitor approved to treat four chronic immune-mediated inflammatory diseases.
Latest News
Topical Tapinarof and Roflumilast for Psoriasis: Where Do they Fit In?
“They’re very fast-acting, effective,” and result in a large improvement over steroids, Dr. Jashin Wu said.
Feature
Ustekinumab’s ‘Egregious’ Medicare Part B and D Pricing Differences Led to Federal Intervention
OIG reports showed a spike in ustekinumab costs for patients in Medicare Part D. Experts said Inflation Reduction Act changes in Medicare drug...
Latest News
TYK2 Inhibitor Effective for Psoriasis in Phase 2 Study
At week 12, PASI 75 was achieved by 18%, 44%, 68%, and 67% of patients receiving zasocitinib at doses of 2 mg, 5 mg, 15 mg, and 30 mg,...
From the Journals
Patients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, Too
GLP-1 RAs were associated with a decreased risk for all-cause mortality and major adverse cardiovascular events in patients with immune-mediated...
Feature
Do You Have Patients With JAKne — JAK Inhibitor–Associated Acne? Here’s What to Know
Janus kinase (JAK) inhibitor-associated acne may be overlooked outside of dermatology, experts said.